Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$PRDL
Took more $PRDL T2 obvious bottom here fins coming by eom lots of patents only a matter of time before the news claps 👏. pic.twitter.com/JC5kVGjfgM
$AAPJ
$AAPJ DD
— 007: A fearless OTC Trader (@shawonsarker84) September 17, 2024
➡️Jan. 24, 2023 Cancel debt $2M Redtail LLC.
➡️$1.3M debt related to real estate offset with asset 1.3M on the book
➡️No plan to do RS in the future
➡️potential acquisition targets gun parts MFG to AI, BTC and blockchain stated July 27,2023
➡️OS and float Maxed at 3B https://t.co/Jgsqeh1fXG pic.twitter.com/sFEDd6iT2T
$CBDW and Adnexus partnership news...
https://finance.yahoo.com/news/adnexus-biotechnologies-partners-1606-corp-120000325.html
$CVKD~ Upcoming Type-B FDA Meeting in September to Discuss Tecarfarin Trial in LVAD Patients
CRTG completed it share exchange agreement with Core Optics Sept 22 2024 . Core Optics projected to make 16 million in 2025 in just one year since they formed July 19 2023 as a private company but now officially public company through the merger The Coretec Group did not have any revenue or products before this merger with CRTG but now have revenue and 90 more patents . The new management should start communicating with the shareholders soon . I believe that the company which is still trading at .015 cents as it did before the close of this merger is undervalued and heres why . Core optics has partnerships with . The company’s distinguished clientele includes Sony, Ford, Hyundai, Samsung, and other major blue-chip companies. and this from the news release Sept 22 https://thecoretecgroup.com/press-releases/the-coretec-group-completes-share-exchange-agreement-with-core-optics/
" As part of the acquisition, Dr. Seonkee Kim has been appointed Chief Executive Officer of Core Optics. Core Optics is a leading manufacturer of testing and calibration equipment for Compact Camera Modules (CCM) used in automobiles, cell phones, and various other consumer and business technology applications. The company’s distinguished clientele includes Sony, Ford, Hyundai, Samsung, and other major blue-chip companies.
This company , Core Optics is out of South Korea where its manufacturing plant is and last july 2023 bought the compact camera module machines from Ismedia which was delisted from he Korean Exchangr where it traded generaly around 10 th 15 bucs a share. Core Optics retooled the CCM machines to test and assemble the CCMs for mostly autos and less for smart phones as autos have 12 cameras per car . So the new machines are already producing revenue in its first year and will hit at least 16 million in 2025 . They have little debt if any and good profit margins ..finacials should be highlighted more when address shareholders soon as they havnt since the close . Core Optics and Core SS llc are Virginia limited liability companies and The Coretec Group CRTG is an Oklahoma LLC . Core Optics LTD is the Korean susidiary but all now under The Coretec Group . They recieved a lot of shares but are all locked up for 6 months and their are 140 million shares in the float . Looking for a good update soon and a complete overview of all the partnerships !! Again i think CRTG is undervalued
From the news release last month
Key Highlights:
Successfully developed the isCrown array system with full automation collimation for 8-degree and 15-degree FOV.
Initiated R&D for Mobileye certification, with completion expected by the end of next year.
Collaborating with Hyundai Mobis on the development of equipment for high-resolution camera modules.
Engaged in a PrePV stage PO process in partnership with Hyundai Mobis.
Completed the delivery of a mass production line for Hyundai’s flagship vehicle camera to a Tier 2 automotive camera supplier in Korea.
$DPUI
$ICTY and $DPUI moving to the LVL! pic.twitter.com/PNPT1CsOop
— Persist1OE (@Persist1OE) September 18, 2024
Here's the full court case
$ICTY heres the court case https://t.co/kQMzOlrXIN pic.twitter.com/GHiDoKm9wQ
— i_like_bb_stock (@thommic) September 18, 2024
$SPCB @ $3.40s: Micro-float R/S play. Trading under cash. EPS. 06 Cyber AI...Last quality R/S micro to rip..Volume & price rising all week. Obvious ripper now. Do not miss $SPCB.
$ATIG New PR Out! First Profits
https://finance.yahoo.com/news/atlantis-gaming-corp-celebrates-first-200500698.html
$GSAC sharing my DD based on recent financials: 1/3
✔️ NO dilution recently
✔️ NICE SS - public float 1.2B; more then 50% of OS is held by insiders; market cap 1.2M
✔️ PRODUCTS and SERVICES - technology for the industrial security and renewable energy markets
$GSAC sharing my DD based on recent financials: 1/3
✔️ NO dilution recently
✔️ NICE SS - public float 1.2B; more then 50% of OS is held by insiders; market cap 1.2M
✔️ PRODUCTS and SERVICES - technology for the industrial security and renewable energy markets pic.twitter.com/ddN4DsEZ3g
$ICTY
Dear $ICTY Shareholders,
I know things have taken longer than expected, and many of you are anxious. Behind the scenes, we’re up to date on filings and working on the first of 4 acquisitions, set to finalize in 3-4 weeks. These moves will add significant value to ICTY.
— Eyecity.com, inc (@EyeCitydotcom) August 28, 2024
QH................................https://stockcharts.com/h-sc/ui?s=QH&p=W&b=5&g=0&id=p84354014936
$SPCB @ $2.90s: AI cyber-security play. Micro-float. Profitable. No debt...Similar to $DTST when that one hit $8.00+ when crowd attacked.
$SPCB now in Full Nasdaq Compliance as of 9/6. News Wire has not yet posted that strong good news. All in all. A home run here. Just add volume and a goner.
Website:
https://www.supercom.com/
$GSAC sharing my DD based on recent financials: 1/3
✔️ NO dilution recently
✔️ NICE SS - public float 1.2B; more then 50% of OS is held by insiders; market cap 1.2M
✔️ PRODUCTS and SERVICES - technology for the industrial security and renewable energy markets
$GSAC sharing my DD based on recent financials: 1/3
— VC (@veronika_1288) May 8, 2024
✔️ NO dilution recently
✔️ NICE SS - public float 1.2B; more then 50% of OS is held by insiders; market cap 1.2M
✔️ PRODUCTS and SERVICES - technology for the industrial security and renewable energy markets pic.twitter.com/ddN4DsEZ3g
$SPCB: Profitable. Low float AI cyber security play now fully Nasdaq Compliant as of last Friday. Great time to load up here. The $TOVX and $RR orbit shot crowd are on $SPCB now. $SPCB ripper on tap.
$ICTY
Dear $ICTY Shareholders,
I know things have taken longer than expected, and many of you are anxious. Behind the scenes, we’re up to date on filings and working on the first of 4 acquisitions, set to finalize in 3-4 weeks. These moves will add significant value to ICTY.
— Eyecity.com, inc (@EyeCitydotcom) August 28, 2024
HI THERE, WHAT ARE THOSE RESTRICTED SHARES ????? $ATIG
$PRDL
Took more $PRDL T2 obvious bottom here fins coming by eom lots of patents only a matter of time before the news claps 👏. pic.twitter.com/JC5kVGjfgM
— Savage (@KEdelbrock)
$TOVX went up 130% in AHs last week....$SPCB @ $2.80s: R/S play. Has $3.54 cash. Float 1.5M. EPS .06 showing same pattern today....$TOVX ripper crowd on $SPCB now...Orbit shot type move developing like $TOVX last week...$RR & $SERV boards also posting $SPCB,,
$ICTY
Dear $ICTY Shareholders,
I know things have taken longer than expected, and many of you are anxious. Behind the scenes, we’re up to date on filings and working on the first of 4 acquisitions, set to finalize in 3-4 weeks. These moves will add significant value to ICTY.
— Eyecity.com, inc (@EyeCitydotcom) August 28, 2024
$$ZIVO Deal Any Day? "Successful Study Funded by Major Animal Health Company"
ZIVO Reports Favorable Results from 42-Day Confirmatory Study of its Coccidiosis Treatment in Broiler Chickens
Aug 23, 2024
BLOOMFIELD HILLS, Mich.--(BUSINESS WIRE)-- ZIVO Bioscience, Inc. (OTCQB: ZIVO), a pioneering biotech/agtech R&D company dedicated to developing therapeutic, medicinal and nutritional product candidates derived from proprietary algal cultures, reports favorable results from its latest 42-day study with its product targeting coccidiosis in broiler chickens.
The study, which was conducted in collaboration with a major global animal health company and replicated real-world poultry production environments, further validates the efficacy of ZIVO’s non-antibiotic, immune-modulating product designed for the treatment of coccidiosis. Funded by the major animal health company, the study focused on the overall health and productivity of birds challenged with the coccidiosis-causing parasite, Eimeria, while comparing administration of ZIVO’s product alone or in combination with either an ionophore-based treatment or a coccidiosis vaccine versus birds treated with the ionophore or vaccination alone. Uninfected/untreated healthy birds and infected/untreated birds served as negative and positive disease controls, respectively.
In this study, broiler chickens infected with coccidiosis and treated with ZIVO’s product in combination with an anticoccidial ionophore or vaccination exhibited statistically significant improvements in both growth performance (as measured by feed conversion ratio, FCR) and clinical signs of disease (as measured by intestinal lesion scores), compared with chickens that received only the ionophore or vaccine. With respect to FCR over the 42-day grow-out period, groups treated with ZIVO’s product in combination with either the ionophore or vaccination performed on par with the healthy, uninfected control group.
“We are delighted to report favorable findings from this new study that confirm the effectiveness of our product to support poultry health and productivity in the presence of coccidiosis. These results further demonstrate the versatility of our product candidate not only because of its ability to enhance currently available treatment options, but also because of its standalone treatment potential as validated in numerous prior studies. Maintaining feed conversion ratios comparable to uninfected birds is a notable finding that underscores the value our product offers the poultry industry,” said John Payne, Chairman and CEO of ZIVO Bioscience.
“Coccidiosis is one of the most challenging and costly diseases in poultry production, and the ability to improve outcomes using our product in combination with existing interventions represents a potential breakthrough in disease management. We look forward to advancing our discussions global animal health companies in preparation for commercial markets,” he added.
About Coccidiosis
Coccidiosis is a protozoal disease that causes diarrhea, weight loss, decreased performance and increased mortality in poultry. This disease represents a significant economic challenge for the global poultry industry, and as indicated by a 2020 study, the estimated annual costs are approximately $14 billioni. Products for treating coccidiosis are mostly antibiotic- or ionophore-based, and no significant new commercial technology has been introduced in the past 60 years. The global poultry industry spends more than $1.5 billion annually on coccidiosis control, primarily using decades-old compounds that industry and consumers alike want to replace due to the risks of developing drug resistance. Coccidiosis is a common disease for chickens, especially among young chicks, and can be fatal or result in compromised digestion.
About ZIVO Bioscience
ZIVO Bioscience is a research and development company with an intellectual property portfolio comprised of proprietary algal and bacterial strains, biologically active molecules and complexes, production techniques, cultivation techniques and patented or patent pending inventions for applications in human and animal health. Please visit www.zivobioscience.com for more information.
$$ATIG New PR Out
Atlantis Gaming Corp. Makes Bold Moves in Real Estate, Embracing a 'Real-Life Monopoly' Strategy
Press Release | 08/29/2024
DETROIT, MI / ACCESSWIRE / August 29, 2024 / Atlantis Gaming Corporation (AGC/ATLANTIS)(OTC PINK:ATIG) is shaking up the gaming industry with a unique "Real-Life Monopoly" acquisition strategy, spearheaded by real estate veteran Herb Strather.
Strather, whose impressive career boasts over $2 billion in closed real estate transactions, is leading AGC's aggressive expansion into real estate. The company is proud to announce the acquisition of the Lahser 6 Apartments, a 54-unit building in Detroit, and has secured a deal to acquire a 55,000 SF modern office building on W. McNichols Rd., also in Detroit.
Both transactions, valued at $2.2 million and $1.8 million respectively, are being executed through a 100% stock swap for equity, showcasing AGC's innovative approach to asset acquisition.
These acquisitions mark a pivotal moment under the leadership of Acting CEO Linda I. Bailey, who is committed to driving AGC's growth following the passing of her husband and former chairman, Donald L. Bailey.
"With over two decades of executive experience with the Atlantis Companies, I am dedicated to realizing the AGC Board's vision through strategic resource allocation and financial growth," said Mrs. Bailey. "This real estate acquisition perfectly aligns with our diversification and asset portfolio enhancement strategy."
The initial transaction involved a stock-for-assets swap with the Grenadier Family, prominent real estate holders in southeast Michigan, and their brokerage firm, Strather Associates.
Detroit's Resurgence Fuels Investment
Detroit's remarkable recovery from its historic bankruptcy has positioned the city as a prime investment hub, attracting global attention. The city's investment-grade credit rating and renewed investor confidence create a fertile ground for AGC's expansion.
Gaming Expertise Meets Real Estate Prowess
AGC's leadership team brings a proven track record in gaming and real estate development. The developers previously created and sold the Motor City Casino for $160 million in profit and have been involved in providing games for state lotteries.
Leveraging this expertise, Atlantis plans to use scratch-off tickets and promotions with state and provincial lotteries, featuring retired athletes, musicians, and celebrities in strategic marketing campaigns.
Additionally, the company is preparing to launch a skill-gaming operator within the next six months, capitalizing on the growing trend of competitive gaming.
Ambitious Growth Plans
This partnership aims to complete $100 million in real estate transactions over the next 60 months, with a robust pipeline of deals and new gaming initiatives already underway.
AGC intends to significantly expand its asset base through acquisitions and financing, targeting a profit of over $2 million and more than $4 million in assets from the two announced transactions alone.
This focus on real estate acquisitions will ensure stability and cash flow while AGC explores new gaming opportunities, marking an exciting new chapter for the company.
About Atlantis Gaming Corporation
Atlantis Gaming Corporation is a dynamic gaming company embracing a "Real-Life Monopoly" strategy to acquire and grow its asset portfolio. With a focus on real estate and innovative gaming ventures, AGC is poised for significant expansion in the coming years.
Contact:
Herb Strather herberts@atlantisgamingcorporation.com PH: 313.444.9691
Linda I. Bailey lindab@atlantisgamingcorporation.com PH: 702.818.1052
###
SOURCE: Atlantis Internet Group Corp.
$ICTY
Dear $ICTY Shareholders,
— Eyecity.com, inc (@EyeCitydotcom) August 28, 2024
I know things have taken longer than expected, and many of you are anxious. Behind the scenes, we’re up to date on filings and working on the first of 4 acquisitions, set to finalize in 3-4 weeks. These moves will add significant value to ICTY.
$PRDL
Took more $PRDL T2 obvious bottom here fins coming by eom lots of patents only a matter of time before the news claps 👏. pic.twitter.com/JC5kVGjfgM
great trip play clean level 2 no dilution it caught some volume
$AAGC Conference call highlights from last night’s call!
🔥🔥 $AAGC 🔥🔥$AAGC 🔥Hollywood Star Cuts! High level points from tonight’s conference call: (Playback posted tomorrow)
— Nickeli (@nickeli54) August 28, 2024
💥Total of 13 new franchise locations opening all completed by March 2025 (30+ locations)
💥 No debt will be taken all cash on hand
💥 Qtr ends next week… pic.twitter.com/mvEkIZaRNM
$PRDL
Took more $PRDL T2 obvious bottom here fins coming by eom lots of patents only a matter of time before the news claps 👏. pic.twitter.com/JC5kVGjfgM
— Savage (@KEdelbrock) March 28, 2024
E S Mining 5-day numbers and the chart today -
https://www.barchart.com/stocks/quotes/ESM.TO/overview Euro Sun Mining Inc (ESM.TO)
0.0600 +0.0050 ( +9.09% ) 10:55 ET [TSX] 5-Day Change+0.0100 ( +22.22% )
Euro Sun Mining Inc (CPNFF)
0.0409 +0.0072 ( +21.36% ) 08/23/24 [OTC US]
https://www.barchart.com/stocks/quotes/CPNFF/overview
TRNR................MULN............................https://www.globenewswire.com/news-release/2024/08/26/2935579/0/en/Volt-Mobility-Enters-into-210-Million-Contract-with-Mullen-Automotive-to-Purchase-3-000-Class-1-and-Class-3-EV-Cargo-Vans-and-Trucks.html
New Update On Brixton Metals (check big shareholders)
https://brixtonmetals.com/presentations/
Source: Markus Mainka / http://www.Shutterstock.com
There’s no such thing as an easy idea for stocks to sell. However, if such a concept exists, discount airliner Spirit Airlines (NYSE:SAVE) would be my choice. Following a denial of a proposed merger with JetBlue Airways (NASDAQ:JBLU), SAVE stock probably can’t be saved. Look, I’m not here to pour salt on open wounds. But the reality is that since the beginning of this year, shares have lost over 84% of equity value.
Sure, it’s risky to actively bet against SAVE stock. According to Fintel, the airliner’s short interest stands at 30.18% of its float. The short interest ratio also lands at 8.4 days to cover. That’s how many trading sessions it would take for the bears to unwind their short positions. However, without the merger, the company simply can’t generate any traction.
Plus, we’re looking at significant problems here. In the best-case scenario, revenue may reach $5.47 billion at the end of fiscal 2025. That’s just 2% higher than 2023’s tally of $5.36 billion. And we’re talking about a discount airliner here: Spirit should be winning on the top line.
Instead, investors will be paying $2.60 per share for levered free cash flow (FCF) of $473 million in the red. That doesn’t seem like a good deal.
Spirit Airlines’SAVE transformation initiatives are commendable. The company’s efforts to upgrade and expand its fleet are also praiseworthy. However, SAVE is grappling with elevated operating expenses and weak liquidity.
Factors Favoring SAVE
In the second quarter of 2024, Spirit Airlines initiated a transformation plan to better align with market dynamics. The introduction of diverse travel options, ranging from premium to budget-friendly, reflects the company's commitment to offering a more personalized and flexible experience for all travelers.
Enhancements like priority check-in, improved boarding and guest-friendly policies demonstrate a clear focus on customer satisfaction and operational efficiency. This move not only aims to attract a broader audience but also positions Spirit to compete more effectively in a dynamic travel industry.
Spirit is set to achieve $100 million in annual cost savings, with $75 million expected by the end of the year 2024. Key initiatives include pausing recruitment, offering unpaid leaves, reducing overhead, furloughing pilots and realigning its network by exiting 42 markets and entering 77 new ones.
SAVE's efforts to expand and modernize its fleet are commendable. The company added eight new A320neo and A321neo aircraft, retired five A319ceo planes and ended the June quarter with 210 aircraft.
Spirit Airlines secured $37.2 million in AOG credits from Pratt & Whitney and recorded $7.1 million in credits. The company expects an average of 20 AOG aircraft in 2024 and plans to negotiate further arrangements after Dec 31, 2024.
Key Risks
Escalated operating expenses are adversely impacting Spirit Airlines’bottom line. This surge in operating expenses is primarily driven by the increase in labor costs and fuel costs.
In the second quarter of 2024, labor costs, comprising salaries and benefits (accounting for 29.2% of the total operating expenses), rose by 2.6% year over year to $418.4 million, and fuel costs surged by 4.2% year over year. The average fuel cost per gallon was pegged at $2.78, indicating a 6.1% year-over-year increase. The average fuel cost per gallon is expected to be $2.65 in the September quarter.
Spirit Airlines exited the second quarter of 2024 with a current ratio (a measure of liquidity) of 0.94, raising liquidity concerns. A current ratio of less than 1 indicates that the company does not have enough cash to meet its short-term obligations. Moreover, Spirit Airlines’high capex raises concerns as a high capex value in times of revenue weakness, as is the case with the company, is not desirable.
Shares of SAVE have decreased 83% over the past year compared to its industry’s growth of 20.1% in the same period.
BOOK VALUE @ PLUS $7
Cash/sh 8.77
they could do reverse though $SAVE
Outstanding Shares
109,518,296
07/24/2024
they had a merger but biden stopped it. it is good for a scalper. ppr is not running away.
SAVE Spirit Airlines Inc
NYSE
55
2.79 0.07 (2.57%)
hi peter, good to hear from you. good morning. how is it going my friend ?????
NBRI .0007 should have hit some radars- up 100% last week on heavy vol. Steady rise-- not a spike- new 52 week high.
Should we buy SAVE?
$GSAC
🚨 $GSAC Next trip runner!
*1.2B float
*No dilution in recent months
*Added 1.2B shares to restricted 👀
- Catalysts:
*Talking about more announcements in the near future related to the acquisition
*upcoming annual report
*Expecting to establish a new research in south africa https://t.co/Z75TJ2uVDU pic.twitter.com/k8Yll9iocq
— NarutOTC (@NarutOTC_) April 11, 2024
TRNR.................MULN..................................https://stockcharts.com/h-sc/ui?s=MULN&p=D&yr=0&mn=2&dy=12&id=p84071410134
https://stockcharts.com/h-sc/ui?s=TRNR&p=D&yr=0&mn=2&dy=12&id=p84071410134
$ATIG Results of most recent test was positive!
Licensing is next!!
MULN........................TRNR....................................https://stockcharts.com/h-sc/ui?s=TRNR&p=D&yr=0&mn=2&dy=12&id=p84071410134
https://stockcharts.com/h-sc/ui?s=MULN&p=D&yr=0&mn=2&dy=12&id=p84071410134
CEO 8% of OS, gold/copper prices up,up this is a opportunity to be soon producer!
https://www.eurosunmining.com/wp-content/uploads/2024/05/20240520-Euro-Sun-PPT.pdf
$ABQQ
$ABQQ
— ABQQ (@ABIntlGroup) August 19, 2024
The Board of Directors decided it would not be in the best interest of the shareholders or the Company to execute a reverse split at this time. Form 8-Khttps://t.co/FoWPxP93K9
$ZIVO The most recent 42 day test should be completed very soon!!!
ZIVO Bioscience, Inc. (NASDAQ: ZIVO): A Promising Biotech Play Targeting the $10 Billion Coccidiosis Market
Published on
August 3, 2024
Overview
ZIVO Bioscience, Inc. (NASDAQ: ZIVO) is a pioneering biotech and agtech research and development company dedicated to developing therapeutic, medicinal, and nutritional product candidates derived from proprietary algal cultures. The company’s intellectual property portfolio includes proprietary algal and bacterial strains, biologically active molecules and complexes, production techniques, cultivation techniques, and patented or patent-pending inventions for applications in human and animal health.
One of ZIVO’s key focus areas is the development of a non-antibiotic, immune-modulating product designed for the prevention and treatment of coccidiosis in broiler chickens. Coccidiosis is a protozoal disease that causes diarrhea, weight loss, decreased performance, and increased mortality in poultry, representing a significant economic challenge for the global poultry industry. The company estimates that coccidiosis costs the poultry industry more than $10 billion annually.
Business Overview
ZIVO’s biotech division is focused on developing therapeutic and medicinal product candidates derived from its proprietary algal culture. The company’s lead product candidate targets coccidiosis in broiler chickens, a disease that has been primarily treated with antibiotic- or ionophore-based products for decades with no significant new commercial technology introduced in the past 60 years.
ZIVO’s agtech division is focused on the production and commercialization of its proprietary algal biomass as a functional food ingredient and nutritional enhancement for human and animal use, as well as a viable functional ingredient for skin care products. The company currently has contracts for the sale and production of its algal biomass, which is being grown in Peru.
Financials
For the fiscal year ended December 31, 2023, ZIVO reported annual revenue of $27,650 and a net loss of $7,777,184. The company’s annual operating cash flow and free cash flow were both -$5,799,893.
In the first quarter of 2024, ZIVO generated revenue of $35,720, a significant increase from the prior-year period when the company had no revenue. However, the company continued to incur a net loss of $1,278,486 during the quarter. ZIVO’s operating cash flow and free cash flow for the first quarter of 2024 were both -$1,699,118.
The company’s financial performance reflects its ongoing investment in research and development activities, as well as the costs associated with building out its commercial operations. ZIVO’s cash position as of March 31, 2024, was $138,641, which the company believes will not be sufficient to fund its operations for the next 12 months. As a result, the company will need to secure additional funding through public or private equity or debt financings, collaborations, or other sources to continue its operations and development activities.
Coccidiosis Treatment Development
ZIVO’s lead product candidate is a non-antibiotic, immune-modulating treatment for coccidiosis in broiler chickens. In July 2024, the company announced the initiation of a 42-day confirmatory study targeting coccidiosis in collaboration with a major global animal health company. This study aims to further validate the efficacy of ZIVO’s product in real-world commercial poultry production environments, building upon the positive outcomes of previous trials.
The study will compare the administration of ZIVO’s product versus an ionophore-based treatment and versus an ionophore-based treatment combined with ZIVO’s product. It will also evaluate the benefits of ZIVO’s product combined with a coccidiosis vaccine versus administration without the vaccine. Results from the study are expected to be available in September 2024.
If the confirmatory study is successful, it could pave the way for the commercialization of ZIVO’s coccidiosis treatment, which would represent a significant opportunity for the company. The global poultry industry spends more than $1.5 billion annually on coccidiosis control, primarily using decades-old compounds that industry and consumers alike want to replace due to the risks of developing drug resistance.
Algal Biomass Production and Commercialization
In addition to its biotech efforts, ZIVO is also focused on the production and commercialization of its proprietary algal biomass. The company currently has contracts for the sale and production of its algal biomass, which is being grown in Peru. ZIVO’s algal biomass contains Vitamin A, protein, iron, important fatty acids, non-starch polysaccharides, and other micronutrients, positioning the product as a viable functional food ingredient and nutritional enhancement for human and animal use, as well as a functional ingredient for skin care products.
ZIVO has engaged an independent distributor, ZWorldwide, Inc., who has begun to sell the company’s algal biomass, branded as ZivolifeTM, with an initial focus on the North American green powder food market. The company is also working towards building commercial-scale algae ponds using a proprietary design and plans to invest in full commercial-scale ponds and product processing equipment once it has successfully grown its algae at a penultimate scale.
Intellectual Property and Partnerships
ZIVO’s intellectual property portfolio is a key asset for the company, comprising proprietary algal and bacterial strains, biologically active molecules and complexes, production techniques, cultivation techniques, and patented or patent-pending inventions for applications in human and animal health.
In addition to its collaboration with the major global animal health company for the coccidiosis treatment confirmatory study, ZIVO has also engaged in other strategic partnerships to advance the development and commercialization of its product candidates. These partnerships have the potential to provide additional funding, expertise, and market access to support the company’s growth.
Risks and Challenges
ZIVO faces several risks and challenges that investors should be aware of. The company’s ability to successfully develop and commercialize its product candidates is subject to regulatory approvals, which can be a lengthy and uncertain process. Additionally, ZIVO may face competition from other companies developing similar products, and there is no guarantee that its products will be accepted by the market or achieve the desired level of commercial success.
The company’s financial position is also a concern, as it currently has limited cash resources and will need to secure additional funding to continue its operations and development activities. If ZIVO is unable to raise the necessary capital, it may be forced to curtail its business operations, including its research and development initiatives.
Outlook
ZIVO Bioscience is a promising biotech and agtech company with a diverse portfolio of product candidates and a focus on addressing significant market opportunities, such as the $10 billion coccidiosis market. The company’s lead product candidate targeting coccidiosis in broiler chickens has the potential to disrupt a market that has been dominated by decades-old antibiotic- and ionophore-based treatments.
The upcoming confirmatory study in collaboration with a major global animal health company will be a crucial milestone for ZIVO, as positive results could accelerate the commercialization of its coccidiosis treatment. Additionally, the company’s efforts to scale up its algal biomass production and commercialize it as a functional food ingredient and nutritional enhancement represent another avenue for growth.
Conclusion
While ZIVO faces financial and regulatory challenges, the company’s innovative product pipeline, intellectual property portfolio, and strategic partnerships position it as a compelling investment opportunity for investors interested in the biotech and agtech sectors. As the company continues to execute on its development and commercialization plans, it will be important to monitor its progress and financial position closely.
$ATIG Atlantis Gaming Corporation ("AGC") Shareholders’ Update
August 13, 2024
Dear Shareholders,
I hope this message finds you well. We begin this update with heavy hearts as we share the sad news of the passing of Donald L. Bailey, the visionary Founder, President, and CEO of Atlantis Gaming Corporation ("AGC"/"ATLANTIS"/OTC PINK: "ATIG"). Don passed away on August 1, 2024. His life's work was a testament to his foresight and dedication to AGC and the broader gaming industry. As we honor his memory, we remain committed to realizing his vision and moving forward with the initiatives he so passionately believed in.
Leadership Transition and Strategic Direction
In light of Donald’s passing, the Board of Directors has appointed me, Linda I. Bailey as Interim Chairman, President, and CEO of AGC. After consultation with our legal and strategic advisors, I have decided to allocate a portion of our family’s stock holdings in AGC to acquire real estate and other valuable assets for the company. This decision aligns with our strategy to enhance AGC’s balance sheet and position the company for growth, especially in the emerging Skill games sector of the market.
Strategic Partnerships and Asset Acquisitions
AGC has entered a strategic relationship with Strather Associates LLC and their partners, CG Properties LLC (Partners); they are long-time investors and major shareholders of AGC. This partnership is a pivotal step in fortifying our asset base and providing liquidity to
complete projects.
Real Estate transactions:
Statement from Herb Strather: “Since we are now into real estate and gaming, we are executing creative, Real- Life Monopoly moves; essentially, we’re bartering a billion shares for real estate deals. You might ask why would someone trade valuable real estate for a penny stock? Good question; as a Coach, Real Estate developer, & Gamer we see the opportunity to get AGC stock price north of $1.00 which being major shareholders benefits us tremendously”.
1. Lahser Six Associates LLC:
o Location: 22009 and 22125-22145 W. McNichols, Detroit, MI
o Transaction: AGC has acquired a 100% interest in this development, at a 10% Cap Rate, fully financed by Partners at $2.2M with a 90-day payment grace period to build up cash reserves. AGC issued 75 million shares at $0.0002 per share. This deal is expected to generate substantial operating capital and represents a win-win for both parties.
2. 11000 W. McNichols:
Description: A 55,000 sq. ft. modern office building in NW Detroit, currently 65% occupied with current lease commitments to reach 85% occupancy.
Acquisition Details: AGC is acquiring this property for $1.8M at an 8% cap rate, with a projected valuation of $2.6M upon full occupancy.
3. 2201 Lawndale:
Description: A 15-unit apartment building in SW Detroit.
Acquisition Strategy: AGC has a one-year option to acquire this asset at a cap rate greater than 10%, free & clear, by bartering 300 million shares.
4. 6442 Michigan Ave.:
o Properties: A 36-unit mixed-use development.
o Strategic Opportunity: These properties have been recently acquired by our partners and are available for AGC’s portfolio at a 10% Cap Rate.
Long-Term Goals
Our long-term goal is to position AGC as a significant player in Detroit’s real estate market, leveraging the city’s ongoing economic recovery. By exchanging blocks of AGC shares for ownership in selected real estate projects and partnering in joint ventures with our partners, we aim to enhance shareholder value and drive sustainable growth. This move is expected to give us long-awaited and needed cash to develop our initiatives.
AGC Gaming Initiatives
AGC remains committed to gaming. With a stronger balance sheet, we can successfully enter the skill gaming market, launch our Ask a Pro and capitalize on our approval from the National Indian Gaming Commission (NIGC) to connect Tribal Casinos across 28 states via a Virtual Private Network (VPN). This approach is a cornerstone of our strategy to enhance our earnings potential by diversifying into real estate with pros and investing in the future of gaming.
AGC has provided seed funding in a young, upcoming skilled gaming enterprise that has figured out the key to stopping credit card fraud which has been most challenging to the industry. The agreement is currently under a confidentiality agreement.
Outlook
With these strategic initiatives and partnerships, AGC is poised to address its cash flow challenges and significantly strengthen its balance sheet. We are confident that these efforts will drive our stock price towards our target of $0.10 per share by
December 31, 2024.
We thank you for your continued support and commitment to AGC. Please visit our website for more information concerning our acquisitions and gaming initiatives at: www.atlantisgamingcorporation.com.
I can also be reached via: lindab@atlantisgamingcorporation.com.
Warm regards,
Linda I. Bailey
Interim Chairman, President, and CEO
Atlantis Gaming Corporation (AGC)
$ATIG Atlantis Gaming Corp is getting ready to move!
New website. New CEO. New Management
https://atlantisgamingcorporation.com/realestate/home.html
Followers
|
1103
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
245657
|
Created
|
02/27/15
|
Type
|
Free
|
Moderator $Pistol Pete$ | |||
Assistants mick balamidas 1jk1 Welcome2Pinkyland BLULLISH Hunchbackgeek |
UPDATE; 5-1-22
courtesy of charting /\ wit tweezer top calls /\ Tony
@Montana_Trades
Really good study sheet on Candlestick Patterns
[-chart]pbs.twimg.com/media/FRn8188XMAAdZvk?format=jpg&name=small[/chart]
GEMOLOGIST /////\\\\\ $Pistol Pete$
FEEL SHARP BE SHARP - $Pistol Pete$
Trade Smarter
The Dream is Free, But The Hustle is Sold Separately - $hrimp2Whale$
Welcoming Introduction for Hunchbackgeek
$ENKS red glare !!!!!
[-chart]investorshub.advfn.com/uimage/uploads/2020/7/11/nbrtddownload.jpeg-2.jpg[/chart]
#66 _________________0
#65 ________________00
#64 _______________0000
#63 ___0__________000000___________0
#62 ___00_________000000___________0
#61 ____0000______000000__________00
#60 ____000000____0000000_____00000
#59 _0_____0000000_000000_00000000___0
#58 00______000000_00000_0000000____00
#57 0000_____000000_000_000000____0000
#56 _000000000__0000_0_000_0_000000000
#55 ____000000000__0_0_0_00000000000
#54 ________000000000000000000000
#53 ______________000_0_0000
#52 ____________00000_0__00000
#51 __________00_______0_______00
#50 ___________________0
#50 ___________________0
#50 ___________________0
#50 ___________________0
#50 ___________________0
HAPPY 4TH OF JULY FROM 1776 / into 2021 AMERICA WILL BE GREAT AGAIN
HALTS & suspensions
https://www.sec.gov/litigation/suspensions.shtml
UT SIGNALS/SELLING/MANY
http://investorshub.advfn.com/boards/msgsearch.aspx?SearchStr=ut
http://www.otcmarkets.com/home
http://www.otcmarkets.com/news/otc-market-headlines?&page=1&pageSize=25
http://otce.finra.org/DailyList
Daily List: Symbol/Name Changes
http://otce.finra.org/DLSymbolNameChanges
Equity Short Interest/ http://otce.finra.org/ESI
Market Statistics/ http://otce.finra.org/MSTop100Issues
Noodls/ http://www.noodls.com/index.asp
Short report/ http://otcshortreport.com/
https://soundcloud.com/thestockradio-com
theStockRadio.com
TSLA/ Tesla Motors (TSLA
http://investorshub.advfn.com/Tesla-Motors-TSLA-18162/
http://investorshub.advfn.com/boards/getboards.aspx?searchstr=tsla
tsla story/
Nikola Tesla 1856 - 1943 and his contribution to science and humanity.
i think was greater than all inventors.
https://www.youtube.com/watch?v=ZZkkHhyWFus
Nikola Tesla's Biography and Life New Full Documentary 2016
https://www.youtube.com/watch?v=hCFtjt-9Sfc
PER IHUB MGMT |
02-07-2021
PER IHUB MGMT
DISCLAIMER: ONLY FOR MICK
https://investorshub.advfn.com/boards/profilea.aspx?user=1012
*The Board Monitor and herewithin , are not licensed brokers and assume NO responsibility for actions,
investments,decisions, or messages posted on this forum.
CONTENT ON THIS FORUM SHOULD NOT BE CONSIDERED ADVISORY NOR SOLICITATION
AUTHORS MAY HAVE BUYS OR SELLS WITH THE COMPANIES MENTIONED IN TRADING POSTERS SHOULD DUE DILIGENT BUYING OR SELLING.
ALL POSTING SHOULD BE CONSIDERED FOR INFORMATION ONLY. WE DO NOT RECOMMEND ANYONE BUY OR SELL ANY SECURITIES POSTED HEREWITHIN.
ANY trade entered into risks the possibility of losing the funds invested.
• There are no guarantees when buying or selling any security.Any
PER IHUB MGMT |
02-07-2021
DISCLAIMER: ONLY FOR MICK
https://investorshub.advfn.com/boards/profilea.aspx?user=1012
*DISCLAIMER *The Board Monitor and herewith, are not licensed brokers and assume NO responsibility for the actions,
investment decisions, and or messages posted on this forum.
• We do NOT recommend that anyone buy or sell any securities posted herewith.
ANY trade entered into risks the possibility of losing the funds invested.
• There are no guarantees when buying or selling any security.Any
Posts Today
|
0
|
Posts (Total)
|
245657
|
Posters
|
|
Moderator
|
|
Assistants
|
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |